As NF1 deficiency mediated escape from BRAF-driven OIS and BRAF inhibitor resistance in melanoma, which could be combatted with MEK inhibitors [18, 19], we hypothesize NF1 loss may be a key targetable mechanism of resistance to PI3K/AKT/mTORC1 inhibitors. Here, BRAF is linked to melanoma.